Glucosamine and Chondroitin Effects

NCT01682694 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-05-28

No results posted yet for this study

Summary

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Conditions

Interventions

DIETARY_SUPPLEMENT

Glucosamine and Chondroitin

Glucosamine (1500 mg) and Chondroitin (1200 mg)

DIETARY_SUPPLEMENT

placebo

Sponsors & Collaborators

  • Fred Hutchinson Cancer Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01682694 on ClinicalTrials.gov